Keros Therapeutics, Inc. ( (KROS) ) has released its Q3 earnings. Here is a breakdown of the information Keros Therapeutics, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, focusing on developing novel therapeutics for disorders related to the transforming growth factor-beta family of proteins. The company is advancing treatments for neuromuscular diseases and cytopenias, including anemia and thrombocytopenia.
In its latest earnings report, Keros Therapeutics highlighted a significant improvement in its financial performance, with total revenue reaching $243.7 million for the nine months ended September 30, 2025, compared to $508,000 in the same period of 2024. This increase was primarily driven by license revenue and service revenue.
Key financial metrics from the report indicate that Keros achieved a net income of $110.5 million for the nine months ended September 30, 2025, a substantial turnaround from the net loss of $141.3 million in the same period of the previous year. The company’s cash and cash equivalents also saw a significant increase, reaching $693.5 million as of September 30, 2025.
Looking ahead, Keros Therapeutics remains focused on advancing its pipeline of product candidates and securing necessary regulatory approvals. The company’s management is optimistic about its financial position and ability to continue operations for at least the next 12 months, despite the challenges of securing additional funding for future development and commercialization efforts.